Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

335
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
335
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

550
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
550
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

913
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
913
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

428
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

490
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
490
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

332
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbene Analogues of Group 15: Reduction of s-Hydrindacene-Based Chloropnictogenium Ions To Access an Antimony Hydride Monocation and a Trinuclear Bismuth Dication.

Journal of the American Chemical Society·2026
Same author

Polymorphic Imidoylamidinato Platinum(II) Complex That Exhibits Inverse Symmetry Breaking Induced by Both Pressure and Temperature.

Journal of the American Chemical Society·2026
Same author

β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NAD<sup>+</sup>-Depletion that Affects the Energy Metabolism of Cultured Primary Rat Astrocytes.

Neurochemical research·2026
Same author

Oxidovanadium(v) coordination compounds based on 1,5-bis(2-hydroxy-3-methoxybenzylidene)carbohydrazide: from discrete to polymeric assemblies.

RSC advances·2026
Same author

Congratulations, JNC Turns 70!

Journal of neurochemistry·2026
Same author

Two-dimensional metal-organic frameworks offer all-in-one cocatalysts for photocatalytic overall water splitting.

Nature chemistry·2026
Same journal

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Journal of medicinal chemistry·2026
Same journal

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Journal of medicinal chemistry·2026
Same journal

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

Journal of medicinal chemistry·2026
Same journal

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Journal of medicinal chemistry·2026
Same journal

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Journal of medicinal chemistry·2026
Same journal

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Dec 9, 2025

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
10:10

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

10.6K

Sila-Ibuprofen.

Florian Kleemiss1,2, Aileen Justies3, Daniel Duvinage1

  • 1University of Bremen, Institute for Inorganic Chemistry and Crystallography, Leobener Str. 3 and 7, 28359 Bremen, Germany.

Journal of Medicinal Chemistry
|September 15, 2020
PubMed
Summary
This summary is machine-generated.

Sila-ibuprofen, a silicon-based nonsteroidal anti-inflammatory drug, shows enhanced solubility and potential for pain relief. This novel compound offers improved properties for medical applications and a deeper understanding of drug-receptor interactions.

More Related Videos

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

3.2K
Author Spotlight: Enhanced Method for Evaluating Analgesic Effects &#8212; Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.4K

Related Experiment Videos

Last Updated: Dec 9, 2025

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
10:10

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

10.6K
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

3.2K
Author Spotlight: Enhanced Method for Evaluating Analgesic Effects &#8212; Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.4K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • Improving the physicochemical properties of existing NSAIDs can enhance their therapeutic potential.
  • Sila-ibuprofen represents a novel silicon-based analog of ibuprofen.

Purpose of the Study:

  • To synthesize and characterize sila-ibuprofen, a silicon-carbon substituted ibuprofen analog.
  • To evaluate the biological activity and toxicology of sila-ibuprofen.
  • To investigate the mechanism of action of sila-ibuprofen on cyclooxygenase enzymes.

Main Methods:

  • Synthesis and characterization of sila-ibuprofen.
  • Solubility and melting enthalpy measurements.
  • Inhibition experiments of cyclooxygenase-I and cyclooxygenase-II (COX-I and COX-II).
  • Computational studies including molecular dynamics, quantum chemistry, and quantum crystallography.

Main Results:

  • Sila-ibuprofen exhibits four times higher solubility in physiological media compared to ibuprofen.
  • A lower melting enthalpy was observed for sila-ibuprofen.
  • Binding affinity to COX-I and COX-II was quantified, revealing contributions from London dispersion and electrostatic interactions.
  • Sila-ibuprofen demonstrates potential for pain relief through COX inhibition.

Conclusions:

  • Sila-ibuprofen possesses improved physicochemical properties, notably enhanced solubility, making it suitable for intravenous administration.
  • The study elucidates the binding interactions of sila-ibuprofen with COX enzymes.
  • Sila-ibuprofen shows promise for medicinal applications and advances the understanding of NSAID mechanisms.